News

Latest news255

Five men stand on stage posing for a photo -- the one in the center holding a ceremonial certificate. A woman, assisting with the event, stands off the side to the left.

Jeremy Alberga, Bakar Labs and QB3 COO, receives UC Berkeley’s Excellence in Management Award

During a period of rapid growth, Alberga leads with both vision and warmth Read post

A symposium to propel ovarian health research beyond the “Dark Ages”

Inspired by breakthroughs in ovarian research, QB3 convened the “Systemic Health Regulated by the Ovarian Pacemaker” symposium on Tuesday, April 14. Scores of researchers, clinicians, biomedical entrepreneurs, and investors converged at Bakar Bio Labs to hear from leaders in ovarian research and learn about the commercialization of, and investment in, new ovarian health technologies. Read post

Startups from UC Berkeley incubator cross $1 billion funding mark

SAN FRANCISCO BUSINESS TIMES – The early results are in — companies birthed or cradled at UC Berkeley's four-year-old Bakar Labs have hit a cumulative funding mark of $1 billion, operators of the incubator say. The total includes money raised by 55 companies currently housed in the incubator or that have graduated to space of their own. Read post
Nine people posing for a group photo

Patient-Centered Endpoints for Biotech Startups: Choosing Outcomes That Matter in the Real World

CURE. – By making endpoints patient-centered from the outset, founders ensure the focus remains on how patients feel, function, and survive, said Amin Zargar, PhD, CEO of ResVita Bio, a company using synthetic biology and metabolic engineering to develop therapies for skin diseases such as Netherton Syndrome. These endpoints reflect the aspects of treatment and disease management that matter most to patients themselves. When defining them, Zargar said, founders should prioritize factors like symptom burden, quality of life, functional status, and treatment tolerability. Read post